ArticleAsian journal of pharmaceutical sciences2022
Impact of the amount of PEG on prodrug nanoassemblies for efficient cancer therapy.
Article in Asian journal of pharmaceutical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 38 citations in OpenAlex.
- Rational engineering of cholesterol-modified prodrug nanoassemblies for improving the tumor selectivity and safety of mitoxantrone.Fundamental research · 2026Article
- Heterocyclic modified paclitaxel prodrug nanoassemblies for stimuli-responsive deliveryActa pharmaceutica Sinica. B · 2026Article
- High-dose treatment of cathepsin B-activatable doxorubicin prodrug nanoparticles that induce tumor-specific immunogenic cell death for immunotherapy of melanoma with minimal systemic toxicity.Asian journal of pharmaceutical sciences · 2026Article
- Recent advances in tumor-activated prodrug nanoparticles for cancer immunotherapy.Frontiers in immunology · 2026Review
- Dual character of surface engineering on SN38 prodrug nano-assemblies: divergent effects on in vitro and in vivo behavior.Military Medical Research · 2025Article
- A comprehensive review on the latest advances of dimeric anticancer prodrugs.Future medicinal chemistry · 2025Review
- A FRET-based off-on AIE nanoprobe enables instant and stain-free detection of hypoxic niches in tumor sections.Theranostics · 2025Article
- A carrier-free long-acting ropivacaine formulation using methylprednisolone sodium succinate as a dual-functional adjuvant.Theranostics · 2025Article
- Precisely Tailoring Molecular Structure of Doxorubicin Prodrugs to Enable Stable Nanoassembly, Rapid Activation, and Potent Antitumor Effect.Pharmaceutics · 2024Article
- A natural compound-empowered podophyllotoxin prodrug nanoassembly magnifies efficacy-toxicity benefits in cancer chemotherapy.Asian journal of pharmaceutical sciences · 2024Article
- Nanotechnology in inflammation: cutting-edge advances in diagnostics, therapeutics and theranostics.Theranostics · 2024Review
- Influence of Different Ratios of DSPE-PEG2k on Ester Prodrug Self-Assembly Nanoparticles for Cell Migration and Proliferation Suppression.International journal of nanomedicine · 2024Article
- Reduction-Responsive Stearyl Alcohol-Cabazitaxel Prodrug Nanoassemblies for Cancer Chemotherapy.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PEGylation has been widely used to improve the pharmacokinetic properties of prodrug self-assembled nanoparticles (prodrug-SANPs). However, the impacts of the amount of PEG on the self-assemble stability, cellular uptake, pharmacokinetics, and antitumor efficacy of prodrug-SANPs are still unknown. Herein, selenoether bond bridged docetaxel dimeric prodrug was synthesized as the model prodrug. Five prodrug-SANPs were designed by using different mass ratios of prodrugs to PEG (W
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.